Low-dose radiation therapy for COVID-19 pneumopathy: what is the evidence?
Strahlenther Onkol
; 196(8): 679-682, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-209949
ABSTRACT
In the current dismal situation of the COVID-19 pandemic, effective management of patients with pneumonia and acute respiratory distress syndrome is of vital importance. Due to the current lack of effective pharmacological concepts, this situation has caused interest in (re)considering historical reports on the treatment of patients with low-dose radiation therapy for pneumonia. Although these historical reports are of low-level evidence per se, hampering recommendations for decision-making in the clinical setting, they indicate effectiveness in the dose range between 0.3 and 1â¯Gy, similar to more recent dose concepts in the treatment of acute and chronic inflammatory/degenerative benign diseases with, e.g., a single dose per fraction of 0.5â¯Gy. This concise review aims to critically review the evidence for low-dose radiation treatment of COVID-19 pneumopathy and discuss whether it is worth investigating in the present clinical situation.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Severe Acute Respiratory Syndrome
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Strahlenther Onkol
Journal subject:
Neoplasms
/
Radiotherapy
Year:
2020
Document Type:
Article
Affiliation country:
S00066-020-01635-7
Similar
MEDLINE
...
LILACS
LIS